These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36197713)

  • 21. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
    Hadjimichael O; Vollmer T; Oleen-Burkey M;
    Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania.
    Duchovskiene N; Mickeviciene D; Jurkeviciene G; Dirziuviene B; Balnyte R
    Mult Scler Relat Disord; 2017 Apr; 13():107-111. PubMed ID: 28427690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study.
    Buard G; Giovannelli J; Outteryck O; Hadhoum N; Lannoy J; Vermersch P; Zéphir H
    Mult Scler Relat Disord; 2019 Aug; 33():39-43. PubMed ID: 31152966
    [No Abstract]   [Full Text] [Related]  

  • 24. [In process].
    Wagner B
    Med Monatsschr Pharm; 2016 Aug; 39(8):352-3. PubMed ID: 29984957
    [No Abstract]   [Full Text] [Related]  

  • 25. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
    Li J; Chikermane SG; Earla JR; Hutton GJ; Aparasu RR
    Mult Scler Relat Disord; 2022 Apr; 60():103703. PubMed ID: 35278846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
    PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disability progression
    von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö
    Mult Scler; 2021 Mar; 27(3):439-448. PubMed ID: 32463336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
    Jakimovski D; Awan S; Eckert SP; Farooq O; Weinstock-Guttman B
    CNS Drugs; 2022 Jan; 36(1):45-59. PubMed ID: 34940954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of fingolimod after switching from interferon β-1a in an adolescent with multiple sclerosis: case report.
    Amidei A; Siciliano G; Pasquali L
    Neurol Sci; 2021 May; 42(Suppl 1):5-7. PubMed ID: 33723709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
    Zettl UK; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Limmroth V;
    BMC Neurol; 2013 Sep; 13():117. PubMed ID: 24011220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on disease-modifying treatments for multiple sclerosis.
    Carrithers MD
    Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Erbay Ö; Usta Yeşilbalkan Ö; Yüceyar N
    J Neurosci Nurs; 2018 Oct; 50(5):291-297. PubMed ID: 30138155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple sclerosis hospitalizations among users of oral disease-modifying therapies.
    Pham Nguyen TP; Jacobs D; Thibault D; Willis AW
    Mult Scler Relat Disord; 2021 Jul; 52():102944. PubMed ID: 33894480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction and escalation therapies in multiple sclerosis.
    Fenu G; Lorefice L; Frau F; Coghe GC; Marrosu MG; Cocco E
    Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):26-34. PubMed ID: 25938688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.